Key result
Synthetic VP1 peptides entrapped into liposomes or coupled to KLH generated the highest anti-VP1 peptide responses and induced both anti-HAV and HAV-neutralizing antibodies in mice.
These mouse findings support advancing liposome- or KLH-formulated VP1 peptides to human trials; leaves open clinical immunogenicity and efficacy against HAV.
Peptide VP1 (11-25) of the capsid of hepatitis A virus was synthesized by the Fmoc-polyamide solid phase method, and administered to mice in different forms: (1) free, (2) encapsulated in multilamellar liposomes, (3) coupled to keyhole limpet hemocyanin (KHL), and (4) incorporated into a tetrameric branched lysine core. The highest anti-VP1 peptide responses were generated by synthetic peptides entrapped into liposomes and coupled to KLH. No anti-HAV response was generated with the free peptide, while all the other forms induced both anti-HAV and HAV-neutralizing antibodies. Maximum neutralization indices were observed in ascites from mice treated with liposome-entrapped and KLH peptides.
No takes yet. Share an insight, caveat, or question.
Haro et al. (1995) studied Hepatitis A virus antibody response. Synthetic VP1 peptide (11-25) in different forms (liposomes, KLH, tetrameric branched lysine core) vs. Free synthetic VP1 peptide was evaluated on Anti-VP1 peptide response and anti-HAV/HAV-neutralizing antibodies. Synthetic VP1 peptides entrapped into liposomes or coupled to KLH generated the highest anti-VP1 peptide responses and induced both anti-HAV and HAV-neutralizing antibodies in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: